BioCentury
ARTICLE | Clinical News

LentiGlobin BB305 gene therapy: Ph I HGB-206 amended

February 9, 2017 9:52 PM UTC

bluebird amended the open-label, U.S. Phase I HGB-206 trial evaluating IV LentiGlobin BB305 to increase production of therapeutic anti-sickling hemoglobin and increase enrollment to up to 29 patients ...

BCIQ Company Profiles

bluebird bio Inc.